PEMF for
Complex Regional Pain Syndrome.

July 2026 · 10 min read · Neurological Protocol

What Is CRPS?

Complex Regional Pain Syndrome (CRPS) is a chronic pain condition characterized by disproportionate, severe, and often progressive pain — typically following trauma, surgery, or fracture — involving autonomic, sensory, motor, and trophic abnormalities. Historically known as Reflex Sympathetic Dystrophy (RSD, Type I) or Causalgia (Type II), CRPS was renamed to reflect its complex, multi-mechanism nature. It most commonly affects the distal extremities — hands, wrists, feet, and ankles — and can spread proximally over time.

Prevalence estimates range from 5.46 to 26.2 per 100,000 per year. The Philippines' high road accident rate (among the highest in Southeast Asia at 12,000+ fatalities annually), its large post-surgical orthopedic population, and a significant diabetic peripheral neuropathy burden (approximately 4.2 million Filipinos with T2DM) all contribute to a substantial CRPS-affected cohort that is almost universally under-recognized and under-treated in current practice.

CRPS Type I vs. Type II

The Budapest Criteria (2004) define two subtypes based on the presence of a definable nerve lesion:

• CRPS Type I (formerly RSD): No identifiable nerve injury confirmed on examination or electrodiagnostic testing. The most common form — typically following a minor injury, surgery, or fracture that does not directly damage a named nerve. The sympathetic and neuroimmune systems amplify pain far beyond what the tissue injury would predict.
• CRPS Type II (formerly Causalgia): Confirmed injury to a specific peripheral nerve (e.g., median nerve at the wrist, ulnar nerve, sciatic nerve). The pain distribution includes but extends beyond the territory of that nerve. Historically the form described in post-battle injuries.

The Budapest Criteria

For a clinical diagnosis of CRPS, the patient must report symptoms and show signs in at least 2 of 4 categories:

The Three-Mechanism Disease Model

CRPS is not a single-mechanism disorder — it is the convergence of at least three reinforcing pathological systems, each requiring its own therapeutic target:

1. Neurogenic inflammation. Peripheral sensitization triggers excessive release of substance P, calcitonin gene-related peptide (CGRP), and pro-inflammatory neuropeptides from primary afferent neurons — causing the classic CRPS triad of erythema, warmth, and edema. This neuroinflammatory cascade upregulates mast cells and activates the complement system locally, amplifying the inflammatory response far beyond the initial injury.
2. Sympathetically maintained pain (SMP). In many CRPS patients, sympathetic efferent fibers develop abnormal coupling with nociceptive afferents — meaning normally non-painful stimuli (light touch, temperature change, movement) are interpreted as pain by the CNS. The HPA axis dysregulation underlying this sympathetic-sensory coupling involves sustained cortisol elevation and reduced parasympathetic tone.
3. Central sensitization. Prolonged nociceptive input from the periphery induces maladaptive neuroplasticity in the spinal dorsal horn and supra-spinal pain-processing centers. Wind-up phenomena, glutamate/NMDA receptor sensitization, and descending pain facilitation create a state where the CNS amplifies all incoming signals — explaining why CRPS pain often spreads beyond the original injury site.

How PEMF Addresses All Three Mechanisms

PEMF is uniquely positioned among physical modalities because it acts at the cellular level across all three CRPS pathways simultaneously:

No dedicated large-sample CRPS-PEMF RCT has been published to date. Clinicians should frame PEMF as an evidence-supported adjunct within a multidisciplinary CRPS program — alongside physiotherapy (graded motor imagery, mirror therapy, desensitization), psychological support, and pharmacological management — not as a standalone treatment.

CRPS Clinical Phases and Treatment Approach

Clinical Protocol

Critical caution: CRPS patients have significantly lowered sensory thresholds and extreme allodynia. PEMF settings must start very low and titrate slowly. High-intensity settings that are standard for musculoskeletal pain can trigger pain flares in CRPS patients. Always begin with the lowest effective intensity and increase only with confirmed patient tolerance session by session.

• Starting frequency: 1–5 Hz (sympathetic modulation); increase to 8–15 Hz by Session 4 if tolerated
• Intensity: begin at 20–30% of device maximum; increase by 5–10% per session if no pain flare
• Coil placement: start proximal to the affected limb (not directly over the allodynic area); progress toward the affected zone as tolerance improves
• Session duration: 20 minutes (acute phase); 30 minutes (subacute/chronic)
• Frequency of sessions: 2 sessions per week in the acute phase; increase to 3/week in subacute/chronic as tolerance is established
• Course length: minimum 20 sessions; outcomes assessment (VAS, Budapest criteria signs, functional questionnaire) at Session 10 and 20
• Integration: ideally scheduled within 24 hours before or after physiotherapy — PEMF's anti-inflammatory and microcirculatory effects prime tissue for manual desensitization work

PEMF vs. Standard CRPS Treatments

Specific Application: Post-Sympathetic Block Window

One of PEMF's highest-value use cases in CRPS management is the post-sympathetic nerve block window. After a successful lumbar sympathetic block or stellate ganglion block, the sympathetically maintained pain temporarily breaks — creating a window of reduced central sensitization where active rehabilitation and physiotherapy are dramatically more effective. PEMF during this post-block window — typically 48–72 hours — consolidates the pain reduction, reduces the neuroinflammatory rebound that otherwise limits block durability, and supports the physiotherapy that follows. This combination positioning makes PEMF an ideal partner for pain intervention specialists and anesthesiologists managing CRPS, rather than a competing service.

Who Is This For?

Key Philippine CRPS patient segments:

• Post-surgical orthopedic patients: CRPS develops in 1–5% of fracture patients and 7% of patients after knee arthroplasty. Post-carpal tunnel surgery, post-Colles' fracture, and post-tibial fracture fixation are the most common triggers in Philippine clinic practice.
• Road accident patients: crush injuries, fracture-dislocations, and nerve injuries from the Philippines' high traffic accident burden generate a significant CRPS-susceptible cohort.
• Post-stroke patients: shoulder-hand syndrome (CRPS Type I following stroke, associated with shoulder subluxation and immobilization) is common in the Philippines' large stroke rehabilitation population.
• Diabetic peripheral neuropathy patients with concurrent trauma: pre-existing nerve vulnerability significantly amplifies the risk of post-traumatic CRPS progression.

Contraindications and Clinical Cautions

• Active cardiac pacemaker or implanted electronic device
• Pregnancy
• Active malignancy in the treatment area
• Active epilepsy (high-frequency protocols)
• CRPS-specific caution: Do not apply high intensity directly over an allodynic zone in acute CRPS. Always start proximal. Rapid intensity escalation can trigger severe pain flares that worsen central sensitization and damage patient trust. Titrate slowly and treat the first session as a dose-finding session.

Frequently Asked Questions

Is CRPS curable?

Early-stage CRPS (within 6–12 months of onset) can achieve full remission in many patients with aggressive multidisciplinary treatment. Chronic CRPS (beyond 12 months with established trophic changes and atrophy) typically shifts toward pain management and functional rehabilitation goals rather than cure. PEMF is positioned as part of the aggressive early-treatment strategy, where it has the greatest potential for meaningful remission.

Can PEMF make CRPS worse?

If applied at too high an intensity directly to an allodynic area in the acute phase, PEMF can trigger a pain flare. This is why the protocol emphasizes starting low, starting proximal, and titrating slowly. When applied correctly, PEMF is generally well tolerated even in hypersensitive CRPS patients. The non-contact nature of PEMF (the coil does not touch the skin) is itself an advantage in patients with severe allodynia who cannot tolerate any skin contact at the affected site.

How does PEMF compare to graded motor imagery (GMI) for CRPS?

Graded motor imagery (GMI) — including mirror therapy, imagined movements, and limb laterality recognition — is one of the strongest evidence-based interventions for CRPS central sensitization. It is entirely compatible with PEMF and ideally combined. GMI directly retrains the cortical body map; PEMF reduces the neuroinflammatory and sympathetic load that is maintaining the sensitized state. The two approaches work on complementary systems and are widely co-prescribed in specialist CRPS programs.

Clinic Investor Takeaway

CRPS patients represent the highest complexity, highest unmet-need segment in Philippine pain medicine. They have typically seen multiple specialists, failed multiple medications, and received limited benefit from standard physiotherapy. PEMF offers a mechanistically rational adjunct at a Philippines-accessible price point (₱30,000–₱50,000 for a 20-session course vs ₱400,000+ for spinal cord stimulation) that no other technology currently matches in the non-invasive space. Clinics that develop a specialist reputation for CRPS — through physiotherapist-PEMF collaboration, referral partnerships with anesthesiologists and orthopedic surgeons, and post-block PEMF protocols — occupy a virtually unchallenged niche in the Philippine pain management landscape. 70+ Israeli clinics (population: 9M) have validated this model — now expanding to the Philippines.